Share

July 16, 2013; 81 (3) Article

Magnetic resonance frequency shifts during acute MS lesion formation

Vanessa Wiggermann, Enedino Hernández Torres, Irene M. Vavasour, G.R. Wayne Moore, Cornelia Laule, Alex L. MacKay, David K.B. Li, Anthony Traboulsee, Alexander Rauscher
First published June 12, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31829bfd63
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
476

Share

Article Information

vol. 81 no. 3 211-218
DOI: 
https://doi.org/10.1212/WNL.0b013e31829bfd63
PubMed: 
23761621
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 9, 2012
  • Accepted in final form April 4, 2013
  • First Published June 12, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Vanessa Wiggermann,
    2. Enedino Hernández Torres, PhD,
    3. Irene M. Vavasour, PhD,
    4. G.R. Wayne Moore, MD,
    5. Cornelia Laule, PhD,
    6. Alex L. MacKay, DPhil,
    7. David K.B. Li, MD,
    8. Anthony Traboulsee, MD and
    9. Alexander Rauscher, PhD
  1. Vanessa Wiggermann,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Enedino Hernández Torres, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Irene M. Vavasour, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) F. Hoffmann-la Roche Ltd. (2) TEVA Neuroscience

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Multiple Sclerosis Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. G.R. Wayne Moore, MD,
    5. Scientific Advisory Boards:

    1. Member of the Medical Advisory Committee of the Multiple Sclerosis Society of Canada

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Teva: Honorarium for speaking at a neurology practicum in 2012.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Schering.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Berlex: Grant-in-aid of research.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Cornelia Laule, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Alex L. MacKay, DPhil,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Cornell University, $1000 honorarium plus travel, Jan 2011 Washington University, $1000 honorarium plus travel, Nov 2011

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. University of British Columbia, Professor

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme Corp, Advanced MRI measures of repair in Alemtuzimab treated patients, $35,000/yr, 2010-2014 Teva Innovation, Remyelination in multiple sclerosis, $46,000/yr, 2010-2014

    Research Support, Government Entities:

    1. NSERC, Proton Magnetic Resonance of Biological Systems, $60,000/yr, 2010-2015 MS Society of Canada, Anatomical and functional MRI correlates of cognitive dysfunction in multiple sclerosis, $92,000/yr, 2010-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. David K.B. Li, MD,
    8. Scientific Advisory Boards:

    1. Served on the Scientific Advisory Board Hoffmann-La Roche, Nuron Biotherapeutics and Data Safety Monitoring Board for Opexa Therapeutics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Consortium of MS Centers

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant to Genzyme

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I am the Director of the UBC MS/MRI Research Group which has been contracted to perform central analysis of MRI scans for therapeutic trials with Angiotech, Bayer, Berlex-Schering, Bio-MS, Centocor, Daiichi Sankyo, Hoffmann-LaRoche, Merck-Serono, Schering-Plough, Teva Neurosciences, Sanofi-Aventis, Transition Therapeutics.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Grant support from MS Society of Canada, Canadian Institute of Health Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Anthony Traboulsee, MD and
    9. Scientific Advisory Boards:

    1. 1. Roche Clinical Trial Steering Committee (2010 ongoing) 2. Merck Serono Data Safety Monitoring Board (2009 ongoing) 3. Neuron Data Safety Monitoring Board (2013 ongoing) 4. MS Society of Canada Minocycline in CIS Clinical Trial Steering Committee (2009 ongoing)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Teva Neuroscience 2. Biogen 3. EMD Serono 4. Sanofi Genzyme 5. Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Chugai Pharmaceuticals

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Sanofi Genzyme 2. Roche 3. Bayer 4. Biogen

    Research Support, Government Entities:

    1. 1. Canadian Institute for Health Research (PI)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. MS Society of Canada 2. Lotte Hecht Foundation 3. Vancouver General and UBC Hospital Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Alexander Rauscher, PhD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Canadian Institutes of Health Research (201109MSH-261306-183304) 2. National Sciences and Engineering Research Council (402039-2011)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the UBC MRI Research Centre (V.W., E.H.T., A.L.M., A.R.), Department of Radiology (V.W., E.H.T., I.M.V., C.L., A.L.M., D.K.B.L., A.R.), Department of Pathology & Laboratory Medicine (G.R.W.M., C.L.), International Collaboration for Repair Discoveries (G.R.W.M.), Department of Physics and Astronomy (A.L.M.), Brain Research Centre (A.L.M., D.K.B.L., A.T., A.R.), and Department of Medicine, Division of Neurology (A.T.), University of British Columbia, Vancouver, Canada.
  1. Correspondence to Dr. Rauscher: rauscher{at}physics.ubc.ca
View Full Text

Article usage

Article usage: June 2013 to May 2023

AbstractFullPdfSource
Jun 2013740056Highwire
Jul 201316883066Highwire
Aug 2013311312Highwire
Sep 201316118Highwire
Oct 201313467Highwire
Nov 20139233Highwire
Dec 20135652Highwire
Jan 20145245Highwire
Jan 2014052pmc
Feb 20144634Highwire
Mar 20144842Highwire
Apr 20146001Highwire
May 20143300Highwire
Jun 20143200Highwire
Jul 20144800Highwire
Aug 20144200Highwire
Sep 20145131Highwire
Oct 20144222Highwire
Nov 20142621Highwire
Dec 20143515Highwire
Jan 20155122Highwire
Jan 20150168pmc
Feb 20155900Highwire
Feb 20150124pmc
Mar 20157001Highwire
Mar 2015053pmc
Apr 20152310Highwire
Apr 20150154pmc
May 20152602Highwire
May 20150143pmc
Jun 20154601Highwire
Jun 2015075pmc
Jul 20156003Highwire
Jul 20150116pmc
Aug 20154600Highwire
Aug 2015052pmc
Sep 20154912Highwire
Sep 20150114pmc
Oct 20152400Highwire
Oct 201501511pmc
Nov 20159200Highwire
Nov 20150168pmc
Dec 20155500Highwire
Dec 2015070pmc
Jan 20164600Highwire
Jan 2016093pmc
Feb 20164500Highwire
Feb 2016074pmc
Mar 20164211Highwire
Mar 2016093pmc
Apr 20164000Highwire
Apr 20160145pmc
May 20162300Highwire
May 20160100pmc
Jun 20165300Highwire
Jun 20160122pmc
Jul 20164800Highwire
Jul 2016081pmc
Aug 201610400Highwire
Aug 2016071pmc
Sep 20167900Highwire
Sep 2016042pmc
Oct 20167700Highwire
Oct 2016084pmc
Nov 20168601Highwire
Nov 20160124pmc
Dec 20167200Highwire
Dec 20160123pmc
Jan 20176800Highwire
Jan 2017031pmc
Feb 20177430Highwire
Feb 2017061pmc
Mar 20179111Highwire
Mar 2017063pmc
Apr 201711700Highwire
Apr 201721011pmc
May 20177600Highwire
May 201711218pmc
Jun 20174600Highwire
Jun 2017378pmc
Jul 20174001Highwire
Jul 201751520pmc
Aug 20174900Highwire
Aug 201721112pmc
Sep 20174000Highwire
Sep 201711011pmc
Oct 20175501Highwire
Oct 201761620pmc
Nov 20172500Highwire
Nov 201721213pmc
Dec 20172611Highwire
Jan 20183642Highwire
Feb 20184222Highwire
Mar 20183900Highwire
Apr 20185400Highwire
Apr 201811516pmc
May 20183131Highwire
Jun 20184500Highwire
Jun 201811010pmc
Jul 20184140Highwire
Aug 20183200Highwire
Aug 2018266pmc
Sep 20183021Highwire
Oct 20184742Highwire
Nov 20183041Highwire
Dec 20184040Highwire
Jan 20192411Highwire
Feb 20194121Highwire
Mar 20192610Highwire
Apr 20194622Highwire
May 20192811Highwire
Jun 20191731Highwire
Jul 20192781Highwire
Aug 20195042Highwire
Sep 20197920Highwire
Oct 20194000Highwire
Nov 20195953Highwire
Dec 20193734Highwire
Jan 20204041Highwire
Feb 20203111Highwire
Mar 20202611Highwire
Apr 20202500Highwire
May 20202311Highwire
Jun 20201200Highwire
Jul 20201700Highwire
Aug 20201600Highwire
Sep 20202500Highwire
Oct 20201200Highwire
Nov 20203410Highwire
Dec 20202600Highwire
Jan 20212931Highwire
Feb 20212552Highwire
Mar 20214200Highwire
Apr 20213200Highwire
May 20213410Highwire
Jun 20212170Highwire
Jul 20212610Highwire
Aug 20212210Highwire
Sep 20212810Highwire
Oct 20214231Highwire
Nov 20213700Highwire
Dec 20213000Highwire
Jan 20224301Highwire
Feb 20223813Highwire
Mar 20225500Highwire
Apr 20225351Highwire
May 20225230Highwire
Jun 20222800Highwire
Jul 20223222Highwire
Aug 202226100Highwire
Sep 20222300Highwire
Oct 20225420Highwire
Nov 20223300Highwire
Dec 20223010Highwire
Jan 20233480Highwire
Feb 20232511Highwire
Mar 20233010Highwire
Apr 20232620Highwire
May 20233211Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles